Interpore Cross International
This article was originally published in The Gray Sheet
Executive Summary
Firm's Pro Osteon 500 bone graft substitute gains FDA approval for expanded indications in treating cysts and tumors in long bones, both in the metaphysis and the diaphysis. The expanded approval via premarket approval application supplement now allows the firm's domestic sales force, which includes direct reps and agents, to promote Pro Osteon to the orthopedic surgical oncologist, the firm says. The product was approved in October 1992 for use in acute, metaphyseal long bone fractures ("The Gray Sheet" Nov. 9, 1992, I&W-4)...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.